Pre-earnings options volume in Aquestive Therapeutics is normal with calls leading puts 20:1. Implied volatility suggests the market is anticipating a move near 12.3%, or 42c, after results are released. Median move over the past eight quarters is 5.1%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Biotech Alert: Searches spiking for these stocks today
- Aquestive Therapeutics receives FDA approval, market access for Libervant
- Largest borrow rate increases among liquid names
- Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
- Aquestive Therapeutics initiated with an Overweight at Piper Sandler